Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527669 | 1.00 | AVPR1A (0.40) | AVPR1ACHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL23304985 | 0.85 | AVPR1A (0.39) | AVPR1ACHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL31059162 | 0.85 | AVPR1A (0.39) | AVPR1ACHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL485825 | 0.83 | AVPR1A (0.43) | AVPR1ACHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL1003364 | 0.82 | AVPR1A (0.43) | AVPR1ACHRNB2CHRNA4 | |
| SCHEMBL30447448 | 0.79 | AVPR1A (0.42) | AVPR1ASIGMAR1 | |
| SCHEMBL14996486 | 0.76 | AVPR1A (0.50) | AVPR1A | |
| SCHEMBL24204169 | 0.76 | AVPR1A (0.45) | AVPR1A | |
| SCHEMBL30447418 | 0.76 | AVPR1A (0.45) | AVPR1A | |
| SCHEMBL23304803 | 0.74 | CHRNB2 (0.38) | AVPR1ACHRNB2CHRNA4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | AVPR1A 2684/4885CHRNB2 4847/4885CHRNA4 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.